The Longitudinal Early-Onset Alzheimer's Disease Study (LEADS) is a NIH funded multi-site study focused on early-onset Alzheimer's Disease #LEADS
Joined September 2019
- Tweets147
- Following235
- Followers1.2K
- Likes252
LEADS retweeted
Here's what you can see from the Apostolova Lab tomorrow, Monday July 17th! #AAIC23 #ENDALZ @ApostolovaLiana
Episode 3 of this up and coming Medscape series is focused on EOAD and LEADS. Heartbreaking!
medscape.com/mtv/alzheimers-…
LEADS retweeted
A great pleasure to work with many field leaders and experts on this meaningful work- @MedscapeNeuro Decision Point: #Alzheimers & related #dementia section.
🫴 Pls check our expert video commentaries on guidelines & practice recommendation. More to come!
decisionpoint.medscape.com/n…
LEADS retweeted
Here is a video of one of my favorite LEADS couples - Mary and Peggy! Mary is one of my bravest patients. She developed problems with memory in her late 50s. Such a heartwarming interview.
Click on the link: youtube.com/watch?v=RtvXb3QB…
Proudly presenting the full-length AAN TV feature of LEADS! #AANAM2023 @AANmember @ApostolovaLiana @DrMariaALZ @AlzIndiana @NeurosciStark @IUMedSchool @iadrc_iu tinyurl.com/4wshajhj
LEADS was featured on AAN TV and recognized as one of the most important AD observational studies. SUCH an honor! @NeurosciStark @iadrc_iu @IUMedSchool #ENDALZ @DrMariaALZ
Indiana University School of Medicine are leading the fight against early-onset AD with The LEADS Study.
Tune into AAN TV for the full video:
youtu.be/90ZLzEXEVJA
#AANAM @AANMember @LEADS_study, @ApostolovaLiana @RabLab_ucsf @dickersonlabMGH @iumedschool
LEADS retweeted
We compared 10 different p-tau assays for detection of amyloid pathology (important for anti-amyloid immunotherapies) and progression to AD dementia (important for prognosis). The results are clear; p-tau217 is the best p-tau biomarker in symptomatic AD, independent of method.
Janelidze et al. test 10 plasma phospho-tau assays head-to-head for their ability to detect abnormal brain amyloid-β status and predict future progression to Alzheimer's dementia in individuals with mild cognitive impairment. bit.ly/3opUmfv
This feature was filmed by AAN TV and will be playing at the AAN in Boston next week. We hope to increase referrals from our fellow neurologists. EOAD is rare. We need your help!
This quoted post is unavailable.
Why is LEADS an important study? Please watch: youtube.com/watch?v=tvqeSQGh…
LEADS retweeted
Great presentation on @LEADS_study at @adpdnet by @ApostolovaLiana of @iadrc_iu @IUMedSchool @NeurosciStark! #ADPD2023
LEADS retweeted
Call for papers for the 2023 DADM special issues:
- IADLs and Neuropsychiatric Symptoms in ADRD
- Sensory Changes in ADRD
- Bayesian Methods that Address the Questions We Actually Ask
The deadline to submit your work is August 15, 2023 @alzdemjournals @WileyNeuro .
LEADS retweeted
Honored to have @ApostolovaLiana as my mentor! She is an exceptional leader and a true source of inspiration and support for everyone in our lab. I am so grateful to be her trainee and to have been a part of this nomination process. Congratulations again!!
LEADS retweeted
Congratulations to @nemes_sara (Apostolova Lab), @NeuroJenya (Saykin and Sporns Labs) and Rachael Deardorff (Saykin Lab) for becoming the recipients of the 2023 John West Scholar Awards from the @iadrc_iu!
LEADS retweeted
Submitted! Crossing my fingers this is how everyone will see me (and my fellow lab mates) in mid-July this year. Go @LEADS_study!!! #AAIC2023
LEADS retweeted
#DADM Editor-in-Chief @ApostolovaLiana of @IndianaUniv is principal investigator of the @LEADS_study, which aims to improve our understanding of, and launch clinical trials in, younger-onset Alzheimer’s. #WomenInScience #NeuroTwitter